An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS- 986177 in Participants With Normal Renal Function and Participants With Moderate and Severe Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2018
At a glance
- Drugs BMS 986177 (Primary)
- Indications Thrombosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 13 Mar 2018 Status changed from recruiting to completed.
- 30 Nov 2017 Status changed from not yet recruiting to recruiting.
- 27 Jun 2017 New trial record